Paul Stoffels,
MD

Executive Vice President, Chief Scientific Officer

Dr. Paul Stoffels is Chief Scientific Officer, Johnson & Johnson. In this role, he works with R&D leaders across Johnson & Johnson to set the enterprise-wide innovation agenda, and is a member of the Johnson & Johnson Executive Committee.

Paul chairs the Johnson & Johnson R&D Management Committee and provides oversight to the Johnson & Johnson Development Corporation (JJDC) and Johnson & Johnson Innovation Centers, with the goal of catalyzing innovative science and technology. Additionally, he oversees product safety of all products of the Johnson & Johnson Family of Companies worldwide.

Paul is also Worldwide Chairman, Pharmaceuticals, Johnson & Johnson, with responsibility for expansion of the company’s therapeutic pipeline through global R&D and strategic partnerships, licensing and acquisitions. He oversees teams across the Janssen Pharmaceutical Companies of Johnson & Johnson, which discover and develop treatments for unmet medical needs in the therapeutic areas of cardiovascular & metabolism, immunology, infectious disease & vaccines, neuroscience and oncology.

Prior to his role as Worldwide Chairman, Paul served as Global Head, Johnson & Johnson Pharmaceutical R&D from 2009 - 2011, as Company Group Chairman, Central Nervous System & Internal Medicine, from 2006 - 2009, and as Company Group Chairman, Global Virology, from 2005-2006. Paul joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of a number of leading products for the treatment of HIV.